Lexaria Bioscience Corp.
LEXX
$4.75
-$1.12-19.01%
NASDAQ
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -7.73M | -9.53M | -10.79M | -11.90M | -11.39M |
| Total Depreciation and Amortization | 106.20K | 117.40K | 100.00K | 115.80K | 112.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 611.80K | 1.03M | 1.12M | 1.14M | 885.60K |
| Change in Net Operating Assets | -411.50K | -992.10K | 863.10K | 195.60K | 693.60K |
| Cash from Operations | -7.43M | -9.37M | -8.71M | -10.45M | -9.70M |
| Capital Expenditure | -40.80K | -40.80K | 0.00 | -24.60K | -67.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -203.20K | -195.50K | -210.30K | -218.40K | -87.10K |
| Cash from Investing | -244.00K | -236.30K | -210.30K | -243.00K | -154.70K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6.52M | 8.21M | 5.17M | 6.05M | 6.05M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6.52M | 8.21M | 5.17M | 6.05M | 6.05M |
| Foreign Exchange rate Adjustments | 34.60K | 62.80K | -53.10K | -50.60K | -59.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.12M | -1.34M | -3.80M | -4.70M | -3.87M |